identified a 10-gene signature based on probable predictive m6a regulatory genes, and these genes (METTL3, WTAP, RBM15, RBM15B, YTHDC2, YTHDF2, HNRNPC, FMR1, LRPPRC, and RBMX) were found to be negatively associated with STAD clinical stage. This evidence concerns the gene YTHDF2 and gastric adenocarcinoma.